NeyroblastGX LLC develops human-induced pluripotent stem cell (HiPSC)-derived organoids and genetically engineered cells for high-throughput screening of drugs, toxicity, and disease pathology in neurodegenerative and infectious diseases, including Alzheimer's and COVID-19. Their platform provides custom-made organoids to facilitate research and therapeutic advancements in these critical health areas.
Funding
$256K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Drug discovery and disease pathology research for neurodegenerative and infectious diseases, such as Alzheimer's and COVID-19, often lack physiologically relevant human models for high-throughput screening. Traditional 2D cell cultures and animal models do not accurately replicate the complexity of human tissues and organs, leading to inaccurate results and hindering therapeutic advancements.
Solution
NeyroblastGX provides human-induced pluripotent stem cell (HiPSC)-derived 3D organoids and genetically engineered cells that mimic human tissues for high-throughput drug screening, toxicity testing, and disease pathology studies. Their platform offers a range of ready-to-use and custom-made organoids, including cerebral and intestinal organoids, as well as various 2D and 3D cell cultures derived from HiPSCs. These advanced cell models enable researchers to study neurological disorders, infectious diseases, and neuron-glial interactions in a more physiologically relevant environment. By using their patent-pending OrGspheroidTM technology, NeyroblastGX can generate specialized organoids such as CSF-secreting choroid plexus (ChP) organoids and blood-brain barrier (BBB) containing CNS organoids.
Target Audience
The primary customers are researchers and pharmaceutical companies involved in drug discovery, toxicity testing, and disease pathology studies, particularly in the fields of neurodegenerative and infectious diseases.
Features
- HiPSC-derived 2D and 3D cell cultures for disease modeling and drug screening
- Ready-to-use 3D organoids, including cerebral and intestinal organoids
- Custom-made organoid generation using patent-pending OrGspheroidTM technology
- HiPSC-derived neural progenitor cells (NPCs) with high expression of SOX2, NESTIN, and PAX6
- HiPSC-derived microglia that efficiently integrate into brain organoids and express IBA1, CD14, and CD45
- HiPSC-derived myeloid dendritic cells (DCs) expressing over 90% CD86+, HLA-DRA+, and MHC Class II+
- Capability to generate CSF-secreting choroid plexus (ChP) organoids and blood-brain barrier (BBB) containing CNS organoids